📰 Nasdaq Atha News
Nasdaq Atha News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Atha. Real-time updates on events, politics, business and more.
February 15, 2024
Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) saw a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 717,600 shares, an increase of 39.6% from the January 15th total of 513,900 shares. Based on an average daily volume of 331,300 shares, the short-interest ratio […]
January 9, 2024
Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) CEO Mark James Litton sold 4,820 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $2.91, for a total value of $14,026.20. Following the sale, the chief executive officer now directly owns 144,397 […]
December 30, 2023
Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) Director Perceptive Advisors Llc purchased 32,134 shares of the stock in a transaction on Wednesday, December 27th. The shares were purchased at an average cost of $2.28 per share, with a total value of $73,265.52. Following the transaction, the director now owns 4,829,412 shares of the company’s […]
November 4, 2023
Athira Pharma (NASDAQ:ATHA – Get Free Report) and Arcellx (NASDAQ:ACLX – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership. Earnings & Valuation This table compares Athira Pharma and […]
October 16, 2023
Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) was the target of a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 741,900 shares, a decline of 7.6% from the September 15th total of 803,300 shares. Based on an average trading volume of 145,700 shares, […]
June 9, 2023
Athira Pharma, Inc. (NASDAQ:ATHA – Get Rating) insider Andrew Gengos purchased 20,012 shares of Athira Pharma stock in a transaction that occurred on Friday, June 2nd. The stock was acquired at an average price of $2.82 per share, with a total value of $56,433.84. Following the transaction, the insider now owns 20,012 shares in the […]
June 7, 2023
Athira Pharma, Inc. (NASDAQ:ATHA – Get Rating) insider Andrew Gengos bought 45,000 shares of the business’s stock in a transaction that occurred on Monday, June 5th. The shares were bought at an average price of $3.00 per share, with a total value of $135,000.00. Following the completion of the purchase, the insider now owns 65,012 […]
June 2, 2023
GSA Capital Partners LLP raised its holdings in Athira Pharma, Inc. (NASDAQ:ATHA – Get Rating) by 59.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 270,989 shares of the company’s stock after purchasing an additional 101,471 shares during the period. GSA Capital Partners LLP’s holdings in Athira Pharma were worth $859,000 at the end […]
May 30, 2023
Athira Pharma, Inc. (NASDAQ:ATHA – Get Rating) was the recipient of a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 2,050,000 shares, a drop of 5.5% from the April 30th total of 2,170,000 shares. Currently, 5.8% of the shares of the company are sold […]
May 19, 2023
Athira Pharma (NASDAQ:ATHA – Get Rating) had its target price cut by Mizuho from $6.00 to $5.00 in a research note released on Monday morning, The Fly reports. Separately, BTIG Research lowered their price target on shares of Athira Pharma from $33.00 to $10.00 and set a buy rating on the stock in a report […]